Clinical trials: Azacitidine
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
Primary Objective: 1. To evaluate whether 5 azacytidine (5-aza)/valproic acid (VPA) or low dose ara-C produces longer event free survival time in patients age > or = 60 years with untreated Acute Myeloid Leukemia (AML) or high…
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
- Trial name
- NCT00382590
- Testing
- 5-Azacytidine, Ara-C, Valproic Acid (VPA)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Myelofibrosis
Ph II Study of Azacitidine in Myelofibrosis
The goal of this clinical research study is to learn if azacitidine can help to control MF. The safety of azacitidine in patients with Myelofibrosis (MF) will also be studied.
- Trial name
- NCT00569660
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to find the highest tolerable dose of Azacytidine (5-azacytidine) combined with cytosine arabinoside (ara-C) for the treatment of patients with relapsed and/or refractory Acute Myeloid…
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
- Trial name
- NCT00569010
- Testing
- Azacitidine, Ara-C
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndrome, Acute Myelogenous Leukemia
Phase II 5-Azacytidine Plus VPA Plus ATRA
5-aza is a chemotherapy drug with activity in leukemia and myelodysplastic syndromes (MDS). Researchers hope that valproic acid (VPA) and all-trans retinoic acid (ATRA)will increase the effects of 5-aza.
- Trial name
- NCT00326170
- Testing
- 5-Azacytidine (5-aza), Valproic Acid, All-Trans Retinoic Acid (ATRA)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Azacitidine in Treating Patients With Myelofibrosis
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00381693
- Testing
- azacitidine
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic